MEA, Saudi Arabia, SEA Car-T Cell Therapy Market - Industry Trends and Forecast to 2031

List of Tables

MEA CAR-T cell therapy treatment market is expected to reach USD 105.69 million by 2031 growing with a CAGR of 28.5% in the forecast period of 2027 to 2031.

Market Segmentation

MEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others), Country (Saudi Arabia, U.A.E., South Africa, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Some of the major factors contributing to the growth of the MEA CAR-T cell therapy treatment market are:

Overview of MEA, Saudi Arabia and SEA CAR-T Cell Therapy Treatment Market Dynamics:

On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells
On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells
On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others
On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others
On the basis of therapeutic application, the market is segmented into diffuse large b-cell lymphoma, follicular lymphoma, Acute Lymphoblastic Leukaemia (ALL), mantle cell lymphoma, multiple myeloma, hematologic malignancies, lung cancer, chronic lymphocytic leukemia, gastric cancer, pancreatic cancer, breast cancer, and others
On the basis of end user, the market is segmented into hospitals, specialty clinics and others
On the basis of distribution channel, the market is segmented into hospitals pharmacy and others

Market Players

Some of the market players operating in the MEA CAR-T cell therapy treatment market are listed below:

Novartis AG,
Gilead Sciences, Inc.,
Bristol-Myers Squibb Company,
Johnson & Johnson Services, Inc.
SEA CAR-T cell therapy treatment market is expected to reach USD 108.95 million by 2031, growing with a CAGR of 30.7% in the forecast period of 2024 to 2031.

Market Segmentation

SEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others), Country (Singapore, Indonesia, Thailand, Malaysia, Philippines, and Vietnam)- Industry Trends and Forecast to 2031

Some of the major factors contributing to the growth of the MEA, Saudi Arabia and SEA CAR-T cell therapy treatment market are:

Overview of SEA CAR-T Cell Therapy Treatment Market Dynamics:

Drivers
Increasing prevalence of cancer and other target diseases
Growing awareness and acceptance of car-t cell therapy
Supportive government initiatives and funding for healthcare innovation
Restraints
High cost of car-t cell therapy
Regulatory hurdles result the delay in car t-cell therapy approval
Opportunities
The extensive pipeline of car-t cell therapy
The development of novel therapies and combination treatments
Challenges
Potential risks and adverse effects of treatment
Competition from alternative treatments and therapies

Market Players

Some of the market players operating in the SEA CAR-T cell therapy treatment market are listed below:

Novartis AG,
Gilead Sciences, Inc.,
Bristol-Myers Squibb Company,
Johnson & Johnson Services, Inc.

1 INTRODUCTION 16

1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 19

2 MARKET SEGMENTATION 21

2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MULTIVARIATE MODELLING 29
2.7 MARKET APPLICATION COVERAGE GRID 29
2.8 PRODUCT LIFELINE CURVE 30
2.9 DBMR MARKET POSITION GRID 31
2.10 VENDOR SHARE ANALYSIS 32
2.11 SECONDARY SOURCES 33
2.12 ASSUMPTIONS 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHT 38

4.1 PESTEL ANALYSIS 39
4.2 PORTER'S FIVE FORCES 40
4.3 PIPELINE ANALYSIS 41

5 MARKET OVERVIEW 45

5.1 DRIVERS 47
- 5.1.1 INCREASING PREVALENCE OF CANCER AND OTHER TARGET DISEASES 47
- 5.1.2 GROWING AWARENESS AND ACCEPTANCE OF CAR-T CELL THERAPY 48
- 5.1.3 SUPPORTIVE GOVERNMENT INITIATIVES AND FUNDING FOR HEALTHCARE INNOVATION 48
5.2 RESTRAINTS 49
- 5.2.1 HIGH COST OF CAR-T CELL THERAPY 49
- 5.2.2 REGULATORY HURDLES RESULT THE DELAY IN CAR T-CELL THERAPY APPROVAL 49
5.3 OPPORTUNITIES 50
- 5.3.1 THE EXTENSIVE PIPELINE OF CAR-T CELL THERAPY 50
- 5.3.2 THE DEVELOPMENT OF NOVEL THERAPIES AND COMBINATION TREATMENTS 50
5.4 CHALLENGES 51
- 5.4.1 POTENTIAL RISKS AND ADVERSE EFFECTS OF TREATMENT 51
- 5.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS AND THERAPIES 52

6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENTN MARKET, BY PRODUCT 53

6.1 OVERVIEW 54
6.2 AUTOLOGOUS CAR-T CELLS 58
6.3 ALLOGENEIC CAR-T CELLS 58

7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY STRUCTURE 59

7.1 OVERVIEW 60
7.2 SECOND GENERATION CAR-T CELLS 64
7.3 THIRD GENERATION CAR-T CELLS 64
7.4 FOURTH GENERATION CAR-T CELLS 64
7.5 FIRST GENERATION CAR-T CELLS 64

8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN 65

8.1 OVERVIEW 66
8.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES 70
- 8.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19) 71
- 8.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30) 71
- 8.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22) 71
- 8.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20) 71
- 8.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33) 71
8.3 ANTIGENS ON SOLID TUMORS 72
8.4 OTHERS 72

9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY BRAND 73

9.1 OVERVIEW 74
9.2 KYMRIAH 78
9.3 YESCARTA 78
9.4 TECARTUS 78
9.5 OTHERS 79

10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY THERAPEUTICS APPLICATION 80

10.1 OVERVIEW 81
10.2 DIFFUSE LARGE B-CELL LYMPHOMA 87
10.3 FOLLICULAR LYMPHOMA 87
10.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) 87
10.5 MANTLE CELL LYMPHOMA 87
10.6 MULTIPLE MYELOMA 87
10.7 LUNG CANCER 87
10.8 CHRONIC LYMPHOCYTIC LEUKEMIA 87
10.9 GASTRIC CANCER 87
10.10 PANCREATIC CANCER 88
10.11 BREAST CANCER 88
10.12 OTHERS 88

11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY END USER 89

11.1 OVERVIEW 90
11.2 HOSPITALS 94
11.3 SPECIALTY CLINICS 94
11.4 OTHERS 94

12 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY, DISTRIBUTION CHANNEL 95

12.1 OVERVIEW 96
12.2 HOSPITAL PHARMACY 100
12.3 OTHERS 100

13 MEA, SAUDI ARABIA, SEA CAR-T CELL THERAPY MARKET, BY COUNTRY 101

13.1 MEA 101
- 13.1.1 SAUDI ARABIA 103
- 13.1.2 U.A.E. 106
- 13.1.3 SOUTH AFRICA 109
- 13.1.4 ISRAEL 112
- 13.1.5 KUWAIT 115
- 13.1.6 EGYPT 118
- 13.1.7 REST OF MIDDLE EAST & AFRICA 121
13.2 SEA 122
- 13.2.1 SINGAPORE 124
- 13.2.2 MALAYSIA 127
- 13.2.3 THAILAND 130
- 13.2.4 INDONESIA 133
- 13.2.5 PHILIPPINES 136
- 13.2.6 VIETNAM 139

14 MEA AND SEA CAR-T CELL THERAPY MARKET: COMPANY LANDSCAPE 142

14.1 COMPANY SHARE ANALYSIS: MEA 142
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 143

15 SWOT ANALYSIS 144

16 COMPANY PROFILE 145

16.1 NOVARTIS AG 145
- 16.1.1 COMPANY SNAPSHOT 145
- 16.1.2 REVENUE ANALYSIS 145
- 16.1.3 PRODUCT PORTFOLIO 146
- 16.1.4 RECENT DEVELOPMENTS 146
16.2 GILEAD SCIENCES, INC. 147
- 16.2.1 COMPANY SNAPSHOT 147
- 16.2.2 REVENUE ANALYSIS 147
- 16.2.3 PRODUCT PORTFOLIO 148
- 16.2.4 RECENT DEVELOPMENTS 148
16.3 BRISTOL-MYERS SQUIBB COMPANY
- 16.3.1 COMPANY SNAPSHOT 149
- 16.3.2 REVENUE ANALYSIS 149
- 16.3.3 PRODUCT PORTFOLIO 150
- 16.3.4 RECENT DEVELOPMENTS 151
16.4 JOHNSON & JOHNSON SERVICES, INC. 152
- 16.4.1 COMPANY SNAPSHOT 152
- 16.4.2 REVENUE ANALYSIS 152
- 16.4.3 PRODUCT PORTFOLIO 153
- 16.4.4 RECENT DEVELOPMENTS 153

17 QUESTIONNAIRE 154

18 RELATED REPORTS 158

LIST OF TABLES

TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS 41
TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA) 47
TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 58
TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 58
TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION) 64
TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION) 64
TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION) 70
TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION) 70
TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 70
TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 71
TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 72
TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 72
TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 78
TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 78
TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION) 86
TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION) 86
TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 94
TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 94
TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 100
TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 100
TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 102
TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 103
TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 103
TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 103
TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 104
TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 104
TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 105
TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 105
TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 105
TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 106
TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 106
TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 106
TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 106
TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 107
TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 107
TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 107
TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 108
TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 109
TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 109
TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 109
TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 110
TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 110
TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 110
TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 111
TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 111
TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 112
TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 112
TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 112
TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 113
TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 113
TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 113
TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 114
TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 114
TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 115
TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 115
TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 115
TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 116
TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 116
TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 116
TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 117
TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 117
TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 118
TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 118
TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 118
TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 118
TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 119
TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 119
TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 119
TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 120
TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 121
TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 123
TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 124
TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 124
TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 124
TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 125
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 125
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 125
TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 126
TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 126
TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 127
TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 127
TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 127
TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 128
TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 128
TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 128
TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 129
TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 129
TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 130
TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 130
TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 130
TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 130
TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 131
TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 131
TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 131
TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 132
TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 133
TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 133
TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 133
TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 134
TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 134
TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 134
TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 135
TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 135
TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 136
TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 136
TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 136
TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 137
TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 137
TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 137
TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 138
TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 138
TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 139
TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION) 139
TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 139
TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION) 139
TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION) 140
TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION) 140
TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 140
TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 141

LIST OF FIGURES

FIGURE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION 21
FIGURE 2 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION 24
FIGURE 3 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS 25
FIGURE 4 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 26
FIGURE 5 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING 29
FIGURE 8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID 29
FIGURE 9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID 31
FIGURE 10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS 32
FIGURE 11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION 37
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET 46
FIGURE 14 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031 54
FIGURE 15 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2024-2031) 55
FIGURE 16 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE 55
FIGURE 17 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031 56
FIGURE 18 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2027-2031) 57
FIGURE 19 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE 57
FIGURE 20 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031 60
FIGURE 21 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2024-2031) 61
FIGURE 22 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE 61
FIGURE 23 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031 62
FIGURE 24 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2027-2031) 63
FIGURE 25 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE 63
FIGURE 26 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031 66
FIGURE 27 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, CAGR (2024-2031) 67
FIGURE 28 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, LIFELINE CURVE 67
FIGURE 29 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031 68
FIGURE 30 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, CAGR (2027-2031) 69
FIGURE 31 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, LIFELINE CURVE 69
FIGURE 32 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031 74
FIGURE 33 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2024-2031) 75
FIGURE 34 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE 75
FIGURE 35 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031 76
FIGURE 36 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, CAGR (2027-2031) 77
FIGURE 37 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, LIFELINE CURVE 77
FIGURE 38 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031 82
FIGURE 39 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, CAGR (2024-2031) 83
FIGURE 40 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE 83
FIGURE 41 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031 84
FIGURE 42 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, CAGR (2027-2031) 85
FIGURE 43 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE 85
FIGURE 44 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031 90
FIGURE 45 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2024-2031) 91
FIGURE 46 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE 91
FIGURE 47 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031 92
FIGURE 48 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2027-2031) 93
FIGURE 49 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE 93
FIGURE 50 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031 96
FIGURE 51 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 97
FIGURE 52 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 97
FIGURE 53 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031 98
FIGURE 54 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2027-2031) 99
FIGURE 55 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 99
FIGURE 56 MEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023) 101
FIGURE 57 SEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023) 122
FIGURE 58 MEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%) 142
FIGURE 59 SEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%) 143

MEA, Saudi Arabia, SEA Car-T Cell Therapy Market - Industry Trends and Forecast to 2031

Description

Table of Contents

List of Tables

Market Segmentation

Some of the major factors contributing to the growth of the MEA CAR-T cell therapy treatment market are:

Overview of MEA, Saudi Arabia and SEA CAR-T Cell Therapy Treatment Market Dynamics:

Market Players

Some of the market players operating in the MEA CAR-T cell therapy treatment market are listed below:

Market Segmentation

Some of the major factors contributing to the growth of the MEA, Saudi Arabia and SEA CAR-T cell therapy treatment market are:

Overview of SEA CAR-T Cell Therapy Treatment Market Dynamics:

Market Players

Some of the market players operating in the SEA CAR-T cell therapy treatment market are listed below:

TABLE OF CONTENTS

1 INTRODUCTION 16

2 MARKET SEGMENTATION 21

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHT 38

5 MARKET OVERVIEW 45

6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENTN MARKET, BY PRODUCT 53

7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY STRUCTURE 59

8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN 65

9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY BRAND 73

10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY THERAPEUTICS APPLICATION 80

11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY END USER 89

12 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY, DISTRIBUTION CHANNEL 95

13 MEA, SAUDI ARABIA, SEA CAR-T CELL THERAPY MARKET, BY COUNTRY 101

14 MEA AND SEA CAR-T CELL THERAPY MARKET: COMPANY LANDSCAPE 142

15 SWOT ANALYSIS 144

16 COMPANY PROFILE 145

17 QUESTIONNAIRE 154

18 RELATED REPORTS 158

LIST OF TABLES

LIST OF FIGURES